Dermatology

Becker recapped hot topics of discussion during a recent HCPLive clinical forum.

The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.

New phase 2 data reveals povorcitinib effectively reduces itch and hives in chronic spontaneous urticaria, showing promise as a treatment option.

At the Fall Clinical Dermatology Conference, this session provided clinical pearls to clinicians in the pediatric dermatology space.

In this episode, the topic of navigating the holiday season and balancing a thriving medical career and a fulfilling family life are highlighted.

This November 18 episode explores early detection, diagnosis, and management of scarring alopecias and hair-care–related hair loss in patients of color.

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

New ACAAI 2025 data show lebrikizumab improves disease control, quality of life, and work productivity in patients of skin of color with moderate to severe atopic dermatitis.

These topline results from the ADHAND trial highlight tralokinumab’s use in adults with atopic dermatitis with moderate-to-severe hand involvement.

The FDA acceptance of Arcutis's supplemental New Drug Application (sNDA) was announced for roflumilast cream 0.3% (Zoryve).

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

Here, we spotlighted 4 late-breaker studies featured in our ACAAI 2025 coverage, along with 2 phase 3 trials.

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

In this Q&A, Soong discusses phase 2 results on povorcitinib, a JAK1 inhibitor that provides rapid relief from chronic spontaneous urticaria symptoms.

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

Gatti highlights the role of social media in dermatology, noting its importance for business growth but emphasizing the need to focus on education.

At ACAAI 2025, Harris spoke with HCPLive about Excellergy’s ECRI program, exploring IgE modulation, safety goals, and potential long-term effects in CSU.

This discussion at the SDPA Fall Conference highlights some scheduling and contract essentials for early career success among physician associates (PAs).

In this interview with Nguyen, Nguyen highlights takeaways from From 'Basement Membrane to Bedside: The Science & Strategy of Bullous Diseases.'

In this segment of his SDPA Fall interview, Nguyen highlighted his second talk ‘Patterns in Red and Purple: Decoding Vasculitis in the Skin.’

This interview features Nguyen discussing his SDPA talk titled ‘The Itch Within: Immune Pathways Driving Chronic Spontaneous Urticaria.’

In this segment of his interview, Abbas highlights when to refer a patient for systemic macrocytosis to a hematology or mast cell disease specialist.

This interview was on-site at SDPA, featuring a discussion of the tools needed to identify systemic macrocytosis.